An observational study in Sickle Cell Trait, sponsored by National Alliance for Sickle Cell Centers. Recruiting at 10 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-06.
Sponsored by National Alliance for Sickle Cell Centers · Observational
The main purpose of this study is to create a longitudinal cohort of those with Sickle Cell Trait (SCT) to better understand the hematologic phenotype for those that carry HbS, assess for differences in those with varying quantities of HbS and assess for potential clinical complications of SCT.
Adults aged 18 and older with sickle cell trait.
Exclusion Criteria:
Other: Biologic Specimen Collection
Participants will have blood and urine collected at Baseline
Hemoglobin variant quantification
Determine range of variability in baseline %HbS in SCT subjects and relationship of baseline %HbS to markers of hemolysis (LDH, reticulocytes, haptoglobin), coagulopathy (D-dimer), and renal disease (urine albumin/creatinine ratio)
Time frame: Through study completion, an average of 2 years
Red blood cell rheology
Identify range of variation in baseline RBC rheological parameters in SCT subjects and relationship to %HbS, other baseline clinical parameters
Time frame: Through study completion, an average of 2 years
Natural History
Evaluate the frequency of hemolysis * Evaluate potential for and progression of chronic kidney disease and albuminuria * Evaluate the relative risk of thrombosis based on medical history * Evaluate the prevalence of episodes of pain or exercise-related symptoms
Time frame: Through study completion, an average of 2 years
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.